Get the Stockscreener App
0.5701
3.65%
0.0201
Dariohealth Corp stock is traded at $0.5701, with a volume of 221.30K.
It is up +3.65% in the last 24 hours and down -18.59% over the past month.
DarioHealth Corp is a digital therapeutics (DTx) company delivering personalized evidence-based interventions that are driven by precision data analytics, software, and personalized coaching. Its cross-functional team operates at the intersection of life sciences, behavioral science, and software technology to deliver seamlessly integrated and engaging digital therapeutics interventions. Also platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health.
See More
Previous Close:
$0.55
Open:
$0.55
24h Volume:
221.30K
Relative Volume:
1.36
Market Cap:
$25.94M
Revenue:
$20.35M
Net Income/Loss:
$-59.43M
P/E Ratio:
-0.5535
EPS:
-1.03
Net Cash Flow:
$-30.96M
1W Performance:
+27.25%
1M Performance:
-18.59%
6M Performance:
-17.38%
1Y Performance:
-37.38%
1-Day Range:
$0.50
$0.58
1-Week Range:
$0.42
$0.58
52-Week Range:
$0.38
$1.55
Dariohealth Corp Stock (DRIO) Company Profile
Name
Dariohealth Corp
Sector
Industry
Phone
972-4-770-6377
Address
322 W 57TH ST. #33B, NEW YORK
Compare DRIO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DRIO
Dariohealth Corp
|
0.5701 | 20.46M | 20.35M | -59.43M | -30.96M | -1.03 |
|
VEEV
Veeva Systems Inc
|
290.86 | 46.10B | 2.86B | 780.66M | 1.19B | 4.72 |
|
TEM
Tempus Ai Inc
|
80.52 | 13.63B | 803.32M | -709.10M | -212.68M | -7.8003 |
|
DOCS
Doximity Inc
|
67.74 | 12.35B | 550.17M | 201.35M | 232.07M | 1.00 |
|
HQY
Healthequity Inc
|
89.82 | 7.74B | 1.15B | 96.70M | -161.99M | 1.09 |
|
WAY
Waystar Holding Corp
|
36.24 | 6.32B | 906.14M | -52.62M | 89.62M | -0.3621 |
Dariohealth Corp Stock (DRIO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-29-25 | Downgrade | TD Cowen | Buy → Hold |
| May-13-22 | Upgrade | Alliance Global Partners | Neutral → Buy |
| Apr-22-21 | Initiated | Cowen | Outperform |
| Mar-23-21 | Initiated | Stifel | Buy |
| Feb-25-21 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-01-21 | Downgrade | Alliance Global Partners | Buy → Neutral |
| Aug-17-20 | Initiated | Aegis Capital | Buy |
| Aug-29-17 | Initiated | Aegis Capital | Buy |
| May-09-16 | Initiated | Rodman & Renshaw | Buy |
View All
Dariohealth Corp Stock (DRIO) Latest News
Why DarioHealth Corp. is moving todayPortfolio Return Summary & Short-Term Trading Alerts - Newser
Momentum divergence signals in DarioHealth Corp. chart2025 Investor Takeaways & Daily Price Action Insights - Newser
How moving averages guide DarioHealth Corp. tradingJuly 2025 Selloffs & Real-Time Volume Analysis - Newser
Can a trend reversal in DarioHealth Corp. lead to recoveryQuarterly Growth Report & Daily Entry Point Alerts - Newser
DarioHealth Corp. Added to High Probability Setup List2025 Market Trends & Expert-Curated Trade Recommendations - newsimpact.co.kr
DarioHealth Corp. stock volume spike explained2025 EndofYear Setup & AI Enhanced Execution Alerts - Newser
Leading vs lagging indicators on DarioHealth Corp. performance2025 Top Gainers & Smart Investment Allocation Tips - Newser
Detecting support and resistance levels for DarioHealth Corp.Quarterly Portfolio Summary & Daily Chart Pattern Signals - Newser
Can trapped investors hope for a rebound in DarioHealth Corp.Share Buyback & Growth Focused Stock Reports - Newser
DarioHealth Corp. stock prediction for this weekMarket Growth Review & Low Risk Entry Point Tips - Newser
Will DarioHealth Corp. see short term momentum2025 Analyst Calls & Weekly Watchlist of Top Performers - Newser
How Efficient Is DarioHealth Corp. at Controlling Operating CostsWeekly Trend Recap & Community Verified Swing Trade Signals - Newser
Risk adjusted return profile for DarioHealth Corp. analyzedEarnings Miss & Weekly Breakout Stock Alerts - Newser
Advanced analytics toolkit walkthrough for DarioHealth Corp.July 2025 Price Swings & Free Expert Approved Momentum Trade Ideas - Newser
Downgrade: Here's How Analysts See DarioHealth Corp. (NASDAQ:DRIO) Performing In The Near Term - simplywall.st
Is This a Bottoming Phase for DarioHealth Corp.2025 Dividend Review & Daily Volume Surge Signals - newsimpact.co.kr
DarioHealth Corp. Outperforms Peers on Volume MetricsM&A Rumor & Verified Momentum Stock Watchlist - newsyoung.net
Trendlines Converge — Decision Point for DarioHealth Corp.2025 Volume Leaders & Expert Approved Momentum Trade Ideas - thegnnews.com
Chartists See Breakout Potential in DarioHealth Corp.July 2025 Setups & Fast Gain Stock Trading Tips - kangso.co.kr
DarioHealth 2025 Q2 Earnings Deepened Losses Despite Revenue Stabilization - AInvest
DarioHealth stock price target lowered to $1.25 at Stifel on revenue miss - Investing.com Canada
Saudi Arabia Blood Glucose Device Market Trends and Company - GlobeNewswire
Saudi Arabia Blood Glucose Device Market Trends and Company Analysis Report 2025-2033 Featuring Abbott Laboratories, Medtronic, Dexcom, Braun, DarioHealth, Sanofi, Bionime, and Novo Nordisk - Yahoo Finance
Technical Heatmap Flags DarioHealth Corp. for WatchEarnings Growth Report & AI Forecast Swing Trade Picks - sundaytimes.kr
DarioHealth shares rise 1.64% premarket after Q2 2025 earnings call. - AInvest
DarioHealth Corp. (NASDAQ:DRIO) Q2 2025 Earnings Call Transcript - Insider Monkey
DarioHealth Corp. (DRIO) Reports Q2 Loss, Misses Revenue Estimates - MSN
DarioHealth Corp (DRIO) Q2 2025 Earnings Call Highlights: Strategic Client Growth Amid Revenue ... By GuruFocus - Investing.com Canada
DarioHealth Reports Increased Losses Amid Revenue Decline - TipRanks
DarioHealth's Q2 2025: Unpacking Contradictions in Revenue Growth, Efficiency, and Pharma Strategy - AInvest
Transcript : DarioHealth Corp., Q2 2025 Earnings Call, Aug 12, 2025 - MarketScreener
DarioHealth Corp. 2025 Q2ResultsEarnings Call Presentation (NASDAQ:DRIO) - Seeking Alpha
Earnings call transcript: DarioHealth Q2 2025 EPS beats, stock falls on revenue miss - Investing.com
Earnings call transcript: DarioHealth Q2 2025 EPS beats, stock falls on revenue miss By Investing.com - Investing.com South Africa
DarioHealth Reports Second Quarter 2025 Financial and Operating Results - The Malaysian Reserve
Dario Q2 rev down 14.3% YoY, gross margin up to 55% YoY. - AInvest
DarioHealth earnings beat by $0.38, revenue fell short of estimates - Investing.com Canada
Digital therapeutics platform DarioHealth Q2 revenue falls steeper-than-expected 14% - MarketScreener
DarioHealth Corp. SEC 10-Q Report - TradingView
What to do if you’re stuck in DarioHealth Corp.Free Alpha Driven Watchlist With Alerts - Newser
DarioHealth To Report Second Quarter 2025 Results On Tuesday, August 12, 2025 - Barchart.com
What's Next: DarioHealth's Earnings Preview - 富途牛牛
Using Bollinger Bands to evaluate DarioHealth Corp.Buy Strategy Review With Performance Summary - Newser
Does DarioHealth Corp. fit your quant trading modelFree Real Profit Trade Plan Suggestions - Newser
DarioHealth DRIO 2025Q2 Earnings Preview Upside Potential on Strong Diabetes Management Growth - AInvest
Analyzing drawdowns of DarioHealth Corp. with statistical toolsSmart Swing Picks with Confirmed Signals - Newser
Market Cool On DarioHealth Corp.'s (NASDAQ:DRIO) Revenues Pushing Shares 25% Lower - 富途牛牛
Visual analytics tools that track DarioHealth Corp. performanceProven Trading System with Consistent Gains - Newser
DarioHealth to Report Second Quarter 2025 Results on Tuesday, August 12, 2025 - Nasdaq
DarioHealth Q2 2025 Earnings: Full Leadership Team to Present Financial Results August 12 Pre-Market - Stock Titan
DarioHealth Corp expected to post a loss of 23 cents a shareEarnings Preview - TradingView
Dariohealth Corp Stock (DRIO) Financials Data
Revenue
Net Income
Cash Flow
EPS
Dariohealth Corp Stock (DRIO) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Nelson Steven Charles | Chief Commercial Officer |
Sep 10 '24 |
Buy |
0.84 |
5,000 |
4,221 |
45,000 |
| Nelson Steven Charles | Chief Commercial Officer |
Sep 11 '24 |
Buy |
0.80 |
5,000 |
4,022 |
50,000 |
| Nelson Steven Charles | Chief Commercial Officer |
Sep 06 '24 |
Buy |
0.84 |
5,000 |
4,200 |
35,000 |
| Nelson Steven Charles | Chief Commercial Officer |
Sep 05 '24 |
Buy |
0.82 |
5,000 |
4,091 |
30,000 |
| Nelson Steven Charles | Chief Commercial Officer |
Sep 09 '24 |
Buy |
0.80 |
5,000 |
4,000 |
40,000 |
| Raphael Erez | Chief Executive Officer |
Aug 27 '24 |
Buy |
0.88 |
5,000 |
4,400 |
1,937,059 |
| Nelson Steven Charles | Chief Commercial Officer |
Aug 23 '24 |
Buy |
0.95 |
5,000 |
4,750 |
25,000 |
| Nelson Steven Charles | Chief Commercial Officer |
Aug 22 '24 |
Buy |
0.94 |
5,000 |
4,725 |
20,000 |
| Nelson Steven Charles | Chief Commercial Officer |
Aug 21 '24 |
Buy |
0.93 |
5,000 |
4,672 |
15,000 |
| Raphael Erez | Chief Executive Officer |
Aug 21 '24 |
Buy |
0.95 |
5,000 |
4,750 |
1,932,059 |
1.72%
0.81%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):